Eton Pharmaceuticals, Inc. (ETON) Form 8-K — Oct 14, 2026
Eton Pharmaceuticals entered an exclusive U.S. license agreement with Aquestive Therapeutics for LIBERVANT (diazepam) buccal film, a treatment for seizure clusters, paying a $10.0 million upfront fee plus up to $47.5 million in milestones and mid-teens royalties on net sales. LIBERVANT holds Orphan Drug Designation and tentative FDA approval, with full approval expected for ages 12+ after VALTOCO's exclusivity expires January 10, 2027, and a PDUFA date of March 29, 2027 for ages 6-11; launch is anticipated in April 2027. The deal expands Eton into neurology with a >$450 million annual U.S.
Key figures
- Royalty rate
- mid-teens percentage of annual net sales
- Total milestones
- up to $47.5 million
- Patent protection
- into 2038
- Anticipated launch
- April 2027
- Upfront license fee
- $10.0 million
- Pdufa date ages 6 11
- March 29, 2027
- Commercial milestones
- up to $35 million
- Us market opportunity
- exceeds $450 million annually
- Patient preference film
- 71% preferred film vs 13% nasal spray
- Valtoco exclusivity expiry
- January 10, 2027
- Milestone ages 6 11 approval
- $2.5 million
- Supply agreement initial term
- 20 years
- Milestone first commercial sale
- $10.0 million (reduced to $5.0 million if ages 2-5 approval not received)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.